ArticleGenes & genomics2026
Anticancer agent FTY720 upregulates cell cycle regulator BTG2 via the SET/TAF-Iβ -PP2A-SMAD3 signaling pathway and induces G2/M arrest in leukemia.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on BTG2 in non‑tumor diseases (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFTY720-mediated disruption of the SET/TAF-Iβ–PP2A complex induces distinct transcriptional changes, highlighting BTG2 as a consistently upregulated target across leukemia models. Integrated analyses reveal that FTY720 suppresses ERK phosphorylation, stabilizes SMAD3, and promotes BTG2 transcription independently of p53 status. These events culminate in G2/M cell-cycle arrest and reflect a potential SET/TAF-Iβ–PP2A–SMAD3–BTG2 signaling pathway. Our findings suggest BTG2 as both a mechanistic effector and a potential prognostic biomarker in myeloid leukemia.
objectiveThis study aims to define the transcriptional consequences of FTY720-mediated disruption of the SET/TAF-Iβ–PP2A complex and to elucidate the molecular mechanism by which FTY720 induces BTG2 expression and antileukemic effects.
methodsWe performed transcriptome analyses of FTY720-treated THP-1 cells and SET/TAF-Iβ-depleted U2OS cells to identify commonly regulated genes and enriched signaling pathways. RT-qPCR, western blotting, co-immunoprecipitation, and ChIP-qPCR were conducted to validate BTG2 induction and investigate the SET/TAF-Iβ–PP2A–SMAD3 regulatory pathway. Cell-cycle effects were evaluated by assessing cyclin B1 and Cdc25C abundance and by performing cell-cycle profiling following FTY720 treatment.
resultsTranscriptome analysis revealed that FTY720 treatment and SET/TAF-Iβ depletion commonly upregulated BTG2, which showed the strongest induction among shared targets. FTY720 stabilized SMAD3 through ERK dephosphorylation and enhanced SMAD3 binding to the BTG2 promoter, leading to increased BTG2 transcription. Functionally, FTY720 reduced cyclin B1 and Cdc25C levels and induced G2/M arrest, consistent with BTG2-mediated cell-cycle regulation.
conclusionThese findings suggest that BTG2 may function as a downstream effector of FTY720-mediated SET/TAF-Iβ inhibition and indicate that a SMAD3-dependent mechanism could contribute to G2/M arrest in leukemia.
Indexed as
Identifiers
41591630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.